A BioPhorum member survey to gather preliminary information from across the biopharmaceutical industry on the characterization and risk assessment of HCP using mass spectrometry.
Host cell protein
Viewing related articles
Enzymatic activity assays – general usage assessment
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member only survey to share knowledge into how, why and when enzymatic activity assays are performed.
Host cell protein risk assessment- Where we are with BioPhorum cross-company collaboration and what we have learnt from an industry perspective?
May 2022 | Conference, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A presentation on cross-company collaborative work and learnings produced from an industry perspective on host cell protein risk assessment. The presentation included a history of the HCP workstream, previous publications, planned future work and publication plans.
How to create a toolbox to assess your high-risk HCPs
Sep 2021 | Development Group, News
Host cell proteins (HCPs) are process-related impurities derived from host cells that may co-purify with a biopharmaceutical drug product. The detection, quantitation, and removal of HCPs from the final biotherapeutic process can be complex and some HCPs can be considered high-risk. They include those that are immunogenic, biologically active, or enzymatically active with the potential to degrade either product molecules or...
“High-risk” host cell proteins (HCPs): A multi-company collaborative view
Sep 2021 | Deliverable, Development Group, Host Cell Protein, Publication
This database and paper provide a comprehensive review and list of potential problematic HCPs that could impact the safety, efficacy, and quality aspects of CHO-produced biologics during their development and manufacturing. They provide a reference on the best practice and control strategy for “high-risk” HCPs” in the biopharmaceutical industry.
Development Group trends and new hot topics
Jul 2020 | Development Group, News
Driven by the ever-increasing need to reduce product development lead times and the opportunities to exploit new technologies in development, BioPhorum Development Group (DG) has taken a detailed look at its portfolio of work and the work of its sponsors. This allowed it to reflect on where and how member companies are engaged. This was an important task and a very successful one and the Phorum is already seeing the impact in everything from...
The BioPhorum and USP collaborative journey to new standards
Apr 2019 | Development Group, Front Page, News
BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration. To this end, USP is engaging with industry to understand its pain points, its challenges and where there is the potential for new standards. “We have been looking at what additional standards we can develop that aren’t necessarily the traditional USP product-specific standards, but that would...
Host cell protein (HCP) : Benchmarking mass spectrometry standards for USP
Mar 2019 | Development Group
This ‘Members Only’ benchmark was used by BioPhorum to initiate discussions with USP to create a common direction on the creation of valuable ‘performance standards’ to identify and quantify host cell proteins (HCPs) using mass spectrometry. As such it provides a valuable survey of the use of mass spectrometry in this domain and the shared priorities in the industry.
Host cell protein risk management paper – part 2
Jul 2018 | Host cell protein, News
The second part of the host cell proteins risk management paper is available here
Host cell protein (HCP): Risk assessment tool and papers
Jun 2018 | Development Group, Host Cell Protein, POI - Development Group
Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs. The complexity and diversity of residual HCP composition in biologics and the incomplete understanding of their potential impact also pose unknown risks besides some of the well-known risks from certain problematic HCPs. This can make the HCP risk assessment and management an industry-wide challenge.
Although attempts have been made to address these challenges in the biopharmaceutical industry, gaps still remain in terms of how to manage the risks associated with HCP during bioprocess development. To this end, a BioPhorum Development Group (BPDG) HCP working team consisting of several companies initiated a collaboration among its members to align industry best practices and generated a generic risk assessment tool to manage HCP-related risks identified during biologics development from both an assay development and process development perspective.
Distinct from individual HCP identity-based safety risk assessment, this tool focuses on the manufacturing process through process development. The tool will help companies to tackle the risks associated with HCP within the development lifecycle. The intent the tool is to provide a template in order to guide process development teams using a scientific knowledge-based risk control strategy, where process or assay changes may be deemed necessary to reduce the risks caused by inadequate removal of HCP upon experimental studies to assess impact of HCPs on product safety, efficacy, and stability.
Companies implementing this risk management model can apply their own unique set of circumstances, products and experience to perform a more comprehensive and robust assessment of risk, identify the priority in which risk reduction steps should be applied.